(CMPS) COMPASS Pathways plc BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(CMPS) COMPASS Pathways plc Complete Analysis Pack
Unlock Strategic Clarity
This COMPASS Pathways plc BCG Matrix helps you see how the company’s products or business units may fit into Stars, Cash Cows, Question Marks, and Dogs for strategy and capital allocation. What you see on this page is a real preview of the analysis, so you can review the format and content before buying. Purchase the full version to get the complete ready-to-use report.
Stars
0 approved star products
By end-2025, COMPASS Pathways plc had 0 approved star products and no commercial therapy on the market. COMP360 was still investigational, so it had no approved sales base or market leadership to drive the Star quadrant.
In BCG terms, the Star space is effectively empty: high-growth demand exists, but Company Name has not converted COMP360 into an approved, revenue-generating product yet.
0 marketed brands
COMPASS Pathways plc had 0 marketed brands, so it had no launched branded medicine to drive sales. In FY2025, revenue still did not come from product sales, which means the business had no true "Star" in BCG terms. Its value remained tied to clinical-stage pipeline progress, not a commercial brand.
1 lead asset, not yet commercial
COMP360 was COMPASS Pathways plc’s lead asset in 2025, but it was still in clinical development and had no commercial sales. The program’s progress could add future value, yet it did not create current market share or recurring revenue. That keeps COMP360 out of the Star box in the BCG Matrix.
Phase IIb TRD program
COMPASS Pathways plc’s Phase IIb TRD program showed real scientific momentum: its 233-patient trial moved COMP360 forward in treatment-resistant depression, a large unmet-need market. But Stars need sales leadership in a growing market, and COMPASS still had no product sales, so this fit is stronger as a pipeline asset than a commercial Star.
- 233-patient Phase IIb trial
- Strong clinical progress
- No commercial sales yet
- Not a BCG Star
Phase II PTSD program
COMPASS Pathways plc’s PTSD program is still in Phase II, so it has clinical upside but no commercial share yet. In BCG terms, that keeps it in a low-share, high-potential bucket, not a Star. With no approved PTSD product, its value is still future optionality.
- Phase II only
- High potential, low share
- Future opportunity, not a Star
COMPASS Pathways: No Stars in FY2025, but COMP360 Keeps Advancing
COMPASS Pathways plc had no Stars in FY2025. COMP360 was still investigational, with no approved sales, no market share, and no recurring product revenue, so it stayed outside the BCG Star box despite a 233-patient Phase IIb TRD trial and ongoing clinical progress.
| Metric | FY2025 |
|---|---|
| Approved products | 0 |
| Product sales | 0 |
| Lead asset | COMP360 |
| Phase IIb TRD patients | 233 |
What is included in the product
Detailed Word Document
BCG Matrix of COMPASS Pathways plc shows pipeline bets, core assets, and divest/hold signals across Stars, Cash Cows, Questions, and Dogs.
Editable Excel File
Clean BCG Matrix for COMPASS Pathways plc, quickly highlighting each segment’s role as a pain point reliever.
Reference Sources
Provides a credible source trail for COMPASS Pathways plc, helping investors quickly verify key claims and make decisions with more confidence.
Cash Cows
0 revenue generators
By end-2025, COMPASS Pathways plc had no product revenue base, so it could not act as a Cash Cow. 2025 revenue was $0, while the company kept funding research and clinical trials, which meant cash outflows still exceeded inflows. A Cash Cow needs stable sales and strong margins, and COMPASS Pathways plc had neither.
0 mature products
COMPASS Pathways plc had 0 mature products, so it had no Cash Cow in the BCG sense. There was no approved therapy or steady product revenue, and the business stayed in development-stage biotech mode, with cash flow still driven by R&D and financing needs rather than product sales.
0 recurring royalties
COMPASS Pathways plc did not disclose any large recurring royalty stream in its latest filings, so there was no product-level cash engine to call a Cash Cow. Its cash inflows still depended on equity or other financing, not passive operating royalties, which is the opposite of the BCG Cash Cow profile. With no commercial product sales base, cash generation stayed tied to funding, not high-margin recurring income.
R&D spend dominated
COMPASS Pathways plc’s R&D spend dominated the cash burn: funds went into psilocybin clinical trials, regulatory work, and manufacturing readiness, not into cash generation. As a pre-revenue business, low-growth harvesting was not available, so the model stayed in investment mode rather than cash-cow mode. Latest filings still show losses and heavy R&D outlays, which keeps this BCG bucket firmly in "question mark" territory.
- R&D drove most cash use.
- Clinical and regulatory work consumed capital.
- Manufacturing readiness added more spend.
- No harvesting without product cash flow.
0 dividend capacity
COMPASS Pathways plc had 0 dividend capacity because it still had no profitable products, so there was no cash surplus to return to shareholders. The business remained capital-consuming, with R&D and operating losses absorbing cash instead of generating a Cash Cow-style surplus. In BCG terms, this was not a cash generator; it was still a funding need.
- No product cash surplus
- Capital-consuming model
- No Cash Cow economics
COMPASS Pathways: No Cash Cow, No Revenue, No Dividend
COMPASS Pathways plc had no Cash Cow in 2025: revenue was $0, and it still ran at a loss while funding clinical and regulatory work. Cash burn stayed tied to R&D, not to stable product sales, so there was no mature, high-margin cash engine to harvest. With 0 approved products and no dividend capacity, the BCG Cash Cow box remained empty.
| 2025 data | Value |
|---|---|
| Revenue | $0 |
| Approved products | 0 |
| Cash Cow status | None |
Full Version Awaits
COMPASS Pathways plc Reference Sources
The COMPASS Pathways plc BCG Matrix preview you see here is the exact same document you’ll receive after purchase. No sample pages, no watermarks, and no placeholder content—just the full, professionally formatted report. Once purchased, the file is instantly available for download and ready to use for analysis, presentations, or strategic planning.
Dogs
0 marketed underperformers
COMPASS Pathways had 0 marketed products in FY2025, so there was no weak-selling brand to defend or divest. The Dog bucket in the BCG matrix was empty because the Company had no commercial portfolio at all. So the analysis stays focused on R&D and pipeline value, not legacy product cleanup.
0 legacy brands
COMPASS Pathways plc had 0 legacy brands, so there was no old consumer or hospital line to trap in Dogs. As a clinical-stage company, it did not have a mature brand base or a broad low-share product tail in 2025. That means no obvious low-growth, low-share cash drain from legacy brands.
Single-asset concentration
COMPASS Pathways plc's value is still concentrated in COMP360, so the Dogs label here is about concentration risk, not a broad weak franchise. If COMP360 fails, a large share of Company Name's equity value can disappear fast, because there is little offset from other assets.
In BCG terms, a failed program would be a write-off, not a defensible Dog with steady cash flow.
High burn, no sales
COMPASS Pathways plc still fits the Dogs risk profile: it kept funding development work while reporting no offsetting commercial revenue, so the business depends on external capital. That makes burn and dilution the main issue, not weak product-market fit.
It is not a commercial Dog yet, because the core asset is still in R&D, not a scaled product line.
- No product sales, so cash burn stays high.
- Financing pressure rises with each trial cycle.
- Risk is stage-based, not demand-based.
Non-core research only
COMPASS Pathways plc’s non-core research is a clear BCG "Dog" only if it stays outside COMP360, which carried the real value: FY2024 R&D was about $89m, showing capital is still directed to the lead asset. Any side projects should be judged fast; if data are weak, cut them before they drain cash. That makes them stop-loss candidates, not long-term holds.
- COMP360 gets priority capital.
- Weak early data means fast exit.
- Non-core work stays secondary.
COMPASS Pathways Had No Dog Assets in FY2025
COMPASS Pathways plc had 0 marketed products in FY2025, so the Dogs bucket stayed empty. With no legacy brands or low-share cash cows, there was no weak commercial asset to harvest or cut. The main risk was not a Dog franchise; it was total dependence on COMP360 and outside funding.
| FY2025 metric | Value |
|---|---|
| Marketed products | 0 |
| Legacy brands | 0 |
| Dog assets | None |
Question Marks
COMP360 psilocybin therapy
COMP360 psilocybin therapy was COMPASS Pathways plc's core investigational asset at end-2025, aimed at treatment-resistant depression, where about 1 in 3 patients do not respond to first-line care. With no approved launch, market share was 0%, so it stayed a pure Question Mark in the BCG Matrix. Its upside hinged on regulatory success, not current sales.
Treatment-resistant depression, Phase IIb
COMPASS Pathways plc’s TRD program moved through Phase IIb with 233 patients, a clear clinical signal in a market that still has high unmet need. In the study, COMP360 25 mg cut MADRS scores by 6.6 points versus placebo at week 3, supporting the next trial stage. But it still needs Phase III success, FDA approval, and real adoption before it can shift from a Question Mark to a Star.
Post-traumatic stress disorder, Phase II
COMPASS Pathways plc’s PTSD program was still in Phase II, so it sits in the Question Mark box: high upside, but high clinical and regulatory risk. PTSD is a large, underserved market, affecting about 3.5% of U.S. adults in a given year and 6.8% over a lifetime. Until Phase II data translate into approval, the program stays speculative.
1-asset pipeline focus
COMPASS Pathways plc’s pipeline is still highly concentrated around COMP360, with no broad late-stage portfolio to offset program risk. That can create strong upside if COMP360 succeeds, but it also means the company needs at least one clear clinical or regulatory win to unlock value.
The market is still pricing a one-asset story: 2024 revenue was $0, and cash and cash equivalents were $127.4 million at 31 December 2024.
- Heavy COMP360 dependence
- High upside, high execution risk
- Needs one win to re-rate
0 commercial share today
COMPASS Pathways plc fits the Question Mark box: it had 0 commercial share at end-2025 because it still had no approved product or sales. The upside is real, but growth depends on Phase 3 data, FDA/EU rulings, and launch execution. If approval lands and uptake is strong, it can move toward Star status; if not, it stays a Question Mark.
- No commercial revenue at end-2025
- 0 market share today
- Value depends on trial and regulatory wins
COMPASS Pathways: All Upside Hangs on COMP360
COMPASS Pathways plc’s Question Mark status is driven by zero revenue, zero market share, and heavy dependence on COMP360. The upside is still clinical, but value now rests on Phase 3, FDA, and EU wins; cash was $127.4 million at 31 Dec 2024.
| Metric | Value |
|---|---|
| Revenue | $0 |
| Market share | 0% |
| Cash | $127.4m |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.